Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05120284 · ClinicalTrials.gov registry record · Phase 2

Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM)

A Phase 2 study of Glioblastoma Multiforme, sponsored by University of Florida.

Active
Registry status
Phase 2
Development phase
40
Enrollment target
2
Study locations

NCT05120284: Active Phase 2 study of Glioblastoma Multiforme, sponsored by University of Florida.

NCT05120284 is a Phase 2 study of Glioblastoma Multiforme that is active but no longer recruiting, run by University of Florida. The registered enrollment target is 40 participants, below the 96-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (58% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05120284, a Phase 2 study of Glioblastoma Multiforme, is active but no longer recruiting, sponsored by University of Florida.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
40 participants
Enrollment target
2
Study locations

Study Summary

Conduct a multicenter, open label Phase IIA trial of oral DCA in 40 surgical patients with recurrent GBM who have clinically indicated debulking surgery planned. No patients will be recruited at UF. Patients will be genotyped to establish safe dosing regimens and will be randomized to receive DCA (N=20) or no DCA (N=20) for one week prior to surgery. Deidentified blood and tumor tissue obtained at surgery will be assessed at UF for biochemical markers of DCA dynamics.

Primary Outcome

The efficacy of dichloroacetate will be determined by the level of phosphorylated PDC protein expressed in surgical tissue.

Conditions Studied

Interventions

  • DRUG Dichloroacetate (DCA)
  • GENETIC Genotype

Study Locations (2)

Maryland

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore

North Carolina

  • Wake Forest University - Winston-Salem

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2022-07-01
Est. Completion 2026-08-31
Phase Phase 2
University of Florida

1,106 total trials

What the registry record for NCT05120284 still lists

NCT05120284 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 96-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (58% lower).

The record links to 1 condition, with Glioblastoma Multiforme appearing as the primary indexed condition, and to 2 interventions - of which Dichloroacetate (DCA) is the first listed.

NCT05120284 reports a single indexed study location in Maryland, North Carolina.

Frequently Asked Questions

What is clinical trial NCT05120284 about?

NCT05120284 is a clinical study titled "Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM)". Conduct a multicenter, open label Phase IIA trial of oral DCA in 40 surgical patients with recurrent GBM who have clinically indicated debulking surgery planned. No patients will be recruited at UF. Patients will be genotyped to establish safe dosing regimens and will be randomized to receive DCA (N...

What is the current status of trial NCT05120284?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2022-07-01. Estimated completion is 2026-08-31.

What conditions does trial NCT05120284 study?

This clinical trial studies the following conditions: Glioblastoma Multiforme.

What interventions are being tested in trial NCT05120284?

The interventions under investigation include: Dichloroacetate (DCA) (DRUG), Genotype (GENETIC).

Who is sponsoring clinical trial NCT05120284?

This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05120284 being conducted?

This trial has 2 study locations across Maryland, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Glioblastoma Multiforme

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05120284's enrollment target sits among peer trials

40 46th of 88 higher than 41 of 88 other Glioblastoma Multiforme trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Glioblastoma Multiforme trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05120284, the US trial registry maintained by the National Library of Medicine. NCT05120284 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.